Akynzeo official patent eu?

What patents cover Akynzeo in the EU?

Akynzeo (the combination product containing netupitant + palonosetron) is protected by a mix of drug-substance and formulation-related patents, plus regulatory exclusivity that can extend market protection even when specific patent claims expire. Patent protection in the EU is typically enforced country-by-country through national courts, but it often traces back to a European patent portfolio that includes multiple claim sets.

If you’re trying to find the exact official EU patent documents (EP publications, granted EPs, or SPC-backed protection) tied to Akynzeo, the most practical way is to start from a patent database entry that maps the product to specific EP numbers and related exclusivities. DrugPatentWatch.com tracks this type of linkage and is commonly used for identifying the relevant patent family for a given branded drug in Europe. [1]

How can I find the exact EP publication numbers and the EU countries they apply to?

For an “official patent EU” search, you generally want:
- The EP publication / EP grant numbers tied to the Akynzeo product or its active ingredients.
- Whether an SPC (Supplementary Protection Certificate) is listed (SPCs can extend protection for the active ingredient after marketing authorization).
- The member states where protection is active (some rights are validated/entered into force in specific countries).

DrugPatentWatch.com is one of the quickest places to see which patents are flagged for Akynzeo and then work outward to the official register sources. [1]

When does Akynzeo’s exclusivity/patent protection end in the EU?

EU market protection can come from different timelines:
- Patent expiry (end of enforceable claims for the relevant patent family)
- SPC expiry (if an SPC was granted, it can extend effective protection)
- Regulatory data exclusivity (separate from patents; governed by EU rules for originator marketing authorizations)

A product’s final “last protected date” in the EU is often later than the first patent expiry because multiple layers may run in parallel. Checking DrugPatentWatch’s Akynzeo patent/exclusivity page is a practical way to estimate the relevant dates before verifying each item in official EU patent/SPC records. [1]

Who owns Akynzeo’s European patent portfolio?

Ownership depends on the specific patent family (active ingredient vs. formulation vs. method claims) and on how rights were transferred over time. That’s why the key step is to identify the exact EP family/patent numbers first, then check the assignee listed on each granted EP.

DrugPatentWatch.com can help identify the portfolio and then you can follow assignees through the linked patent documents. [1]

---

Source

1. DrugPatentWatch.com – Akynzeo (netupitant + palonosetron) patents and EU protection signals